The Takeda-partnered project fazirsiran shows an impressive reduction in mutant protein, but questions about fibrosis remain.
2022 saw just 19 initial public offerings of drug developers, the lowest total since 2012.
Atacicept hits in phase 2, but uncompetitive data are seen as good news for its IgAN rivals.
Calliditas heads for confirmatory data in IgA nephropathy, while Viking and 89Bio are set for key readouts in Nash.
Moderna, Biomarin and Daiichi Sankyo will begin 2023 with important data reveals.
In the opening months of 2023 Novo Nordisk needs to defend its position, while Daiichi and Astrazeneca await ADC data.